DYN — Dyne Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Sarepta, Dyne sink after Novartis muscle disorder trial failure
Brief: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Dyne Therapeutics, Inc reports results for the quarter ended June 30 - Earnings Summary
Dyne Therapeutics reports larger-than-expected Q2 net loss per share
Brief: Dyne Therapeutics Announces U.S. FDA Clearance Of Investigational New Drug (Ind) Application For Dyne-302 In Facioscapulohumeral Muscular Dystrophy (Fshd)
Brief: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Wabtec, Chubb, CME Group
U.S. STOCKS ON THE MOVE-Wabtec, Johnson & Johnson, CME Group
U.S. STOCKS ON THE MOVE-GE Vernova, Arrowhead Pharma
U.S. STOCKS ON THE MOVE-AT&T, Cal-Maine Foods, OraSure Technologies
Dyne Therapeutics falls after upsized $375 mln share sale
Brief: Dyne Therapeutics, - Announces Pricing Of Upsized Offering Of 18.3 Million Shares At $20.50 Per Share
Dyne Therapeutics tumbles after beginning $300 mln stock offering